| Literature DB >> 31148341 |
Chanmi Cho1,2,3, Li-Jung Kang1,2,3, Dain Jang1,2,3, Jimin Jeon1,2,3, Hyemi Lee1,2,3, Sangil Choi1,2,3, Seong Jae Han1,2,3, Eunjeong Oh1,2,3, Jiho Nam1,2,3, Chun Sung Kim4, Eunkuk Park1,5, Seon-Yong Jeong1,5, Chan Hum Park6, Yu Su Shin6, Seong-Il Eyun7, Siyoung Yang1,2,3.
Abstract
Although Hif-2α is a master regulator of catabolic factor expression in osteoarthritis development, Hif-2α inhibitors remain undeveloped. The aim of this study was to determine whether Cirsium japonicum var. maackii (CJM) extract and one of its constituents, apigenin, could attenuate the Hif-2α-induced cartilage destruction implicated in osteoarthritis progression. In vitro and in vivo studies demonstrated that CJM reduced the IL-1β-, IL-6, IL-17- and TNF-α-induced up-regulation of MMP3, MMP13, ADAMTS4, ADAMTS5 and COX-2 and blocked osteoarthritis development in a destabilization of the medial meniscus mouse model. Activation of Hif-2α, which directly up-regulates MMP3, MMP13, ADAMTS4, IL-6 and COX-2 expression, is inhibited by CJM extract. Although cirsimarin, cirsimaritin and apigenin are components of CJM and can reduce inflammation, only apigenin effectively reduced Hif-2α expression and inhibited Hif-2α-induced MMP3, MMP13, ADAMTS4, IL-6 and COX-2 expression in articular chondrocytes. IL-1β induction of JNK phosphorylation and IκB degradation, representing a critical pathway for Hif-2α expression, was completely blocked by apigenin in a concentration-dependent manner. Collectively, these effects indicate that CJM and one of its most potent constituents, apigenin, can lead to the development of therapeutic agents for blocking osteoarthritis development as novel Hif-2α inhibitors.Entities:
Keywords: Cirsium japonicum var. maackii; Cox-2; Hif-2α; Mmp; apigenin; osteoarthritis
Mesh:
Substances:
Year: 2019 PMID: 31148341 PMCID: PMC6652892 DOI: 10.1111/jcmm.14418
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Figure 1Cirsium japonicum var. maackii inhibits IL‐1β‐, IL‐6‐, IL‐17‐ and TNF‐α‐induced Mmp3, Mmp13 and Cox‐2 expression in articular chondrocytes. A and B, Chondrocytes treated with IL‐1β (1 ng/mL) were treated with or without various concentrations of Cirsium japonicum var. maackii extract for 24 h (n = 5). The expression of Mmp3, Mmp13 and Cox‐2 was determined by RT‐PCR (A, left), qRT‐PCR (A, right), Western blot (B, left) and densitometry (B, right). Gapdh and ERK were used as loading controls for PCR and Western blotting respectively. Chondrocytes treated with IL‐6 (100 ng/mL) (C), IL‐17 (10 ng/mL) (D) and TNF‐α (50 ng/mL) (E) were co‐treated with Cirsium japonicum var. maackii extract for 24 h at the indicated concentrations. The expression of Mmp3, Mmp13 and Cox‐2 was determined by qRT‐PCR. Data were analysed using two‐tailed t tests. Values represent the means ± SEM; **P < 0.005
Figure 2Oral administration of Cirsium japonicum var. maackii protects against cartilage destruction in OA development. A, Experimental scheme for analysis of the DMM‐induced OA model. B, Mice with DMM were treated three times a week with Cirsium japonicum var. maackii extract or PBS via oral gavage for 10 weeks. Cartilage destruction was detected by Safranin O staining. C, Cartilage destruction was quantified by OARSI scores (upper panel) and subchondral bone thickness (lower panel) at 10 weeks following surgery (n = 10). Scale bar: 50 µm. Data were analysed using one‐way ANOVA with Bonferroni's test or a non‐parametric Mann‐Whitney U test. Values represent the means ± SEM; **P < 0.005
Figure 3Cirsium japonicum var. maackii reduces Hif‐2α overexpression‐induced Mmp3, Mmp13 and Cox‐2 expression and attenuates Hif‐2α overexpression‐induced cartilage destruction. A, Chondrocytes were either untreated or treated with the indicated amount of Cirsium japonicum var. maackii extract and exposed to IL‐1β for 24 h (n = 5). Hif‐2α expression was analysed by RT‐PCR (upper panel) and qRT‐PCR (lower panel). B, Chondrocytes were transduced with Ad‐C or Ad‐Hif‐2α (800 MOI) and then treated with the indicated concentrations of Cirsium japonicum var. maackii for 24 h (n = 5). Western blot, RT‐PCR (left panel) and qRT‐PCR (right panel) are shown. Representative RT‐PCR gels are presented in A from more than five independent experiments using different sets of primary chondrocyte cultures. C and D, Mice were IA‐injected with Ad‐C or Ad‐Hif‐2α (1 × 109 PFU) and then orally administered Cirsium japonicum var. maackii extract (n = 10). Representative images of cartilage sections stained with Safranin O (C), OARSI grades (D, upper panel) and subchondral bone plate thickness (D, lower panel) are shown. Scale bar: 50 µm. Data were analysed using two‐tailed t‐tests (B) and one‐way ANOVA with Bonferroni's test (D). Values represent the means ± SEM; **P < 0.005
Figure 4Apigenin regulates catabolic factor expression via Hif‐2α regulation. A, HPLC spectra of cirsimarin, cirsimaritin and apigenin in Cirsium japonicum var. maackii and the standard compounds. B‐D, Chondrocytes were either untreated or treated with the indicated amount of cirsimarin (B), cirsimaritin (C) or apigenin (D) and exposed to IL‐1β for 24 h (n = 5). Expression of Hif‐2α, Mmp3, Mmp13 and Cox‐2 was analysed by RT‐PCR (left panel) and qRT‐PCR (right panel). E, Chondrocytes were transduced with Ad‐C or Ad‐Hif‐2α (800 MOI) and then treated with the indicated concentrations of apigenin for 24 h. Western blot, RT‐PCR (left panel) and qRT‐PCR (right panel) are shown (n = 5). Representative RT‐PCR gels are presented in A‐D from more than five independent experiments using different sets of primary chondrocyte cultures. Data were analysed using two‐tailed t‐tests. Values represent the means ± SEM; *P < 0.05, **P < 0.005
Figure 5Apigenin and Cirsium japonicum var. maackii directly regulate Mmp3, Mmp13, Adamts4 and Cox‐2 transcriptional activity. A‐D, Chondrocytes were co‐transfected with Hif‐2α vector and Mmp3 (A), Mmp13 (B), Adamts4 (C) or Cox‐2 (D) promoter‐driven reporter vectors and then treated with the indicated concentrations of Cirsium japonicum var. maackii extract or apigenin for 24 h (n = 5). Data were analysed using two‐tailed t‐tests. Values represent the means ± SEM; **P < 0.005
Figure 6Apigenin regulates Hif‐2α expression via NF‐κB and JNK pathways. A and B, Chondrocytes were pre‐treated with different concentrations of apigenin for 24 h prior to treatment with IL‐1β (1 ng/mL) for 10 min (n = 5). IκB and phosphorylated JNK (pJNK) levels were measured by Western blotting (A) and densitometry (B). ERK and JNK were used as loading controls. Data were analysed using two‐tailed t‐tests. Values represent the means ± SEM; **P < 0.005